A new study published in the Journal of Affective Disorders has found that adults with major depression show specific ...

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the ...

A generative AI–powered therapy chatbot is linked to significant reductions in symptoms of depression, anxiety, and eating ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

In light of these findings, Axsome has announced plans to initiate a Phase 3 trial focusing exclusively on MDD patients with EDS in 2025. This decision comes after observing clinically meaningful and ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

Discover the 6 types of depression affecting millions of Americans, their causes, warning signs, and effective treatments ...

Everyone experiences occasional ups and downs. However, dramatic mood swings and emotional instability that disrupt relationships, work or school and daily living could signal something more: ...

Policy update increases access for millions covered by Evernorth Health ServicesMALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial ...

Study finds AI chatbot significantly improve symptoms for those suffering from major depressive disorder (MDD), generalized ...

Dynamic interpersonal therapy (DIT) is a short-term psychodynamic psychotherapy that has been shown to effectively reduce depressive symptoms in patients with major depressive disorder (MDD). In DIT, ...

Neuronetics' strategic acquisitions, including Greenbrook, and FDA approvals are expected to drive revenue growth. See why ...